Recurrent Rectal Cancer Terminated Phase 1 Trials for Sargramostim (DB00020)

Also known as: Rectal cancer recurrent / Carcinoma rectum recurrent / Rectal carcinoma recurrent / Carcinoma of rectum recurrent

IndicationStatusPhase
DBCOND0028583 (Recurrent Rectal Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00088933Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal CancerTreatment